Melt-extruded orally administrable opioid formulations
AssigneeEuro-Celtique S.A.
InventorsBenjamin Oshlack, Mark Chasin, Hua-Pin Huang, David Sackler
Life of this patent
Estimating the term…
Abstract
Bioavailable sustained release oral opioid analgesic dosage forms, comprising a plurality of multiparticulates produced via melt extrusion techniques are disclosed.
Claims24
A sustained-release pharmaceutical formulation, comprising a melt-extruded blend of a therapeutically active agent, one or more hydrophobic materials selected from the group consisting of alkylcelluloses, acrylic and methacrylic acid polymers and copolymers, shellac, zein, hydrogenated castor oil, hydrogenated vegetable oil, and mixtures thereof;
- and one or more hydrophobic fusible carriers which provide a further retardant effect and selected from the group consisting of natural or synthetic waxes, fatty acids, fatty alcohols, and mixtures thereof, said hydrophobic fusible carrier having a melting point from 30 to 200° C., said melt-extruded blend divided into a unit dose containing an effective amount of said therapeutically active agent to render a desired therapeutic effect and providing a sustained-release of said therapeutically active agent for a time period of from about 8 to about 24 hours.
A method of preparing a sustained-release pharmaceutical extrudate suitable for oral administration, comprising:
- blending a therapeutically active agent together with (1) a hydrophobic material selected from the group consisting of alkylcelluloses, acrylic and methacrylic acid polymers and copolymers, shellac, zein, hydrogenated castor oil, hydrogenated vegetable oil, and mixtures thereof and (2) a hydrophobic fusible carrier selected from the group consisting of natural or synthetic waxes, fatty acids, fatty alcohols, and mixtures thereof;
- said retardant material having a melting point between 30-200° C. and being included in an amount sufficient to further slow the release of the therapeutically active agent,
- heating said blend to a temperature sufficient to soften the mixture sufficiently to extrude the same;
- extruding said heated mixture as a strand having a diameter of from 0.1-3 mm;
- cooling said strand;
- and
- dividing said strand to form non-spheroidal multi-particulates of said extrudate having a length from 0.1-5 mm;
- and
- dividing said non-spheroidal multi-particulates into unit doses containing an effective amount of said therapeutically active agent, said unit dose providing a sustained-release of said therapeutically active agent for a time period of from about 8 to about 24 hours.
A sustained-released pharmaceutical formulation, comprising a melt-extruded blend of an opioid analgesic and one or more hydrophobic materials selected from the group consisting of alkylcelluloses, acrylic and methacrylic acid polymers and copolymers, shellac, zein, hydrogenated castor oil, hydrogenated vegetable oil, and mixtures thereof;
- said melt-extruded blend divided into a unit dose containing an effective amount of said therapeutically active agent to render a desired therapeutic effect and providing a sustained-release of said therapeutically active agent for a time period of from about 8 hours to about 24 hours.
Dependencies are inferred from the claim text.